Cleveland BioLabs and Panacela Labs have signed a contract with the Ministry of Industry and Trade of the Russian Federation for the development of Xenomycins, a family of anti-infective agents. The contract, valued at approximately $4.6 million, was issued under the Russian Federation’s “Pharma 2020” development initiative and provides matching funding for approximately three years to support preclinical and clinical studies.   Xenomycins present a new mode of targeting DNA in pathogenic ...